Faraz S Ahmad1, Iben M Ricket2, Bradley G Hammill3,4, Lisa Eskenazi4, Holly R Robertson4, Lesley H Curtis4, Cecilia D Dobi5, Saket Girotra6,7, Kevin Haynes8, Jorge R Kizer9,10, Sunil Kripalani11, Mathew T Roe3,4, Christianne L Roumie11, Russ Waitman12, W Schuyler Jones3,4, Mark G Weiner13. 1. Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (F.S.A.). 2. Louisiana Public Health Institute, New Orleans (I.M.R.). 3. Duke University School of Medicine, Durham, NC (B.G.H., M.T.R., W.S.J.). 4. Duke Clinical Research Institute, Durham, NC (B.G.H., L.E., H.R., L.H.C., M.T.R., W.S.J.). 5. Department of Clinical Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (C.D.D.). 6. University of Iowa Carver College of Medicine, Iowa City (S.G.). 7. Iowa City Veteran Affairs Medical Center (S.G.). 8. Scientific Affairs, HealthCore, Inc., Wilmington, DE (K.H.). 9. Cardiology Section, San Francisco Veterans Affairs Health Care System, CA (J.R.K.). 10. Department of Medicine and Department of Epidemiology and Biostatistics, University of California San Francisco (J.R.K.). 11. Department of Medicine, Vanderbilt University Medical Center, Veterans Health Administration-Tennessee Valley Healthcare System Geriatric Research Education Clinical Center, Health Services Research and Development Center, Nashville, TN (S.K., C.L.R.). 12. Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS (R.W.). 13. Department of Population Health Sciences, Weill Cornell Medicine, New York Presbyterian-Weill Cornell Campus, New York (M.G.W.).
Abstract
BACKGROUND: Many large-scale cardiovascular clinical trials are plagued with escalating costs and low enrollment. Implementing a computable phenotype, which is a set of executable algorithms, to identify a group of clinical characteristics derivable from electronic health records or administrative claims records, is essential to successful recruitment in large-scale pragmatic clinical trials. This methods paper provides an overview of the development and implementation of a computable phenotype in ADAPTABLE (Aspirin Dosing: a Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness)-a pragmatic, randomized, open-label clinical trial testing the optimal dose of aspirin for secondary prevention of atherosclerotic cardiovascular disease events. METHODS AND RESULTS: A multidisciplinary team developed and tested the computable phenotype to identify adults ≥18 years of age with a history of atherosclerotic cardiovascular disease without safety concerns around using aspirin and meeting trial eligibility criteria. Using the computable phenotype, investigators identified over 650 000 potentially eligible patients from the 40 participating sites from Patient-Centered Outcomes Research Network-a network of Clinical Data Research Networks, Patient-Powered Research Networks, and Health Plan Research Networks. Leveraging diverse recruitment methods, sites enrolled 15 076 participants from April 2016 to June 2019. During the process of developing and implementing the ADAPTABLE computable phenotype, several key lessons were learned. The accuracy and utility of a computable phenotype are dependent on the quality of the source data, which can be variable even with a common data model. Local validation and modification were required based on site factors, such as recruitment strategies, data quality, and local coding patterns. Sustained collaboration among a diverse team of researchers is needed during computable phenotype development and implementation. CONCLUSIONS: The ADAPTABLE computable phenotype served as an efficient method to recruit patients in a multisite pragmatic clinical trial. This process of development and implementation will be informative for future large-scale, pragmatic clinical trials. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02697916.
RCT Entities:
BACKGROUND: Many large-scale cardiovascular clinical trials are plagued with escalating costs and low enrollment. Implementing a computable phenotype, which is a set of executable algorithms, to identify a group of clinical characteristics derivable from electronic health records or administrative claims records, is essential to successful recruitment in large-scale pragmatic clinical trials. This methods paper provides an overview of the development and implementation of a computable phenotype in ADAPTABLE (Aspirin Dosing: a Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness)-a pragmatic, randomized, open-label clinical trial testing the optimal dose of aspirin for secondary prevention of atherosclerotic cardiovascular disease events. METHODS AND RESULTS: A multidisciplinary team developed and tested the computable phenotype to identify adults ≥18 years of age with a history of atherosclerotic cardiovascular disease without safety concerns around using aspirin and meeting trial eligibility criteria. Using the computable phenotype, investigators identified over 650 000 potentially eligible patients from the 40 participating sites from Patient-Centered Outcomes Research Network-a network of Clinical Data Research Networks, Patient-Powered Research Networks, and Health Plan Research Networks. Leveraging diverse recruitment methods, sites enrolled 15 076 participants from April 2016 to June 2019. During the process of developing and implementing the ADAPTABLE computable phenotype, several key lessons were learned. The accuracy and utility of a computable phenotype are dependent on the quality of the source data, which can be variable even with a common data model. Local validation and modification were required based on site factors, such as recruitment strategies, data quality, and local coding patterns. Sustained collaboration among a diverse team of researchers is needed during computable phenotype development and implementation. CONCLUSIONS: The ADAPTABLE computable phenotype served as an efficient method to recruit patients in a multisite pragmatic clinical trial. This process of development and implementation will be informative for future large-scale, pragmatic clinical trials. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02697916.
Authors: Zubin J Eapen; John P Vavalle; Christopher B Granger; Robert A Harrington; Eric D Peterson; Robert M Califf Journal: Am Heart J Date: 2013-03-13 Impact factor: 4.749
Authors: Rachel L Richesson; W Ed Hammond; Meredith Nahm; Douglas Wixted; Gregory E Simon; Jennifer G Robinson; Alan E Bauck; Denise Cifelli; Michelle M Smerek; John Dickerson; Reesa L Laws; Rosemary A Madigan; Shelley A Rusincovitch; Cynthia Kluchar; Robert M Califf Journal: J Am Med Inform Assoc Date: 2013-08-16 Impact factor: 4.497
Authors: Rachel L Richesson; Beverly B Green; Reesa Laws; Jon Puro; Michael G Kahn; Alan Bauck; Michelle Smerek; Erik G Van Eaton; Meredith Zozus; W Ed Hammond; Kari A Stephens; Greg E Simon Journal: J Am Med Inform Assoc Date: 2017-09-01 Impact factor: 4.497
Authors: Aziz A Boxwala; Mor Peleg; Samson Tu; Omolola Ogunyemi; Qing T Zeng; Dongwen Wang; Vimla L Patel; Robert A Greenes; Edward H Shortliffe Journal: J Biomed Inform Date: 2004-06 Impact factor: 6.317
Authors: William R Hersh; Mark G Weiner; Peter J Embi; Judith R Logan; Philip R O Payne; Elmer V Bernstam; Harold P Lehmann; George Hripcsak; Timothy H Hartzog; James J Cimino; Joel H Saltz Journal: Med Care Date: 2013-08 Impact factor: 2.983
Authors: Alvina G Lai; Wai Hoong Chang; Constantinos A Parisinos; Michail Katsoulis; Ruth M Blackburn; Anoop D Shah; Vincent Nguyen; Spiros Denaxas; George Davey Smith; Tom R Gaunt; Krishnarajah Nirantharakumar; Murray P Cox; Donall Forde; Folkert W Asselbergs; Steve Harris; Sylvia Richardson; Reecha Sofat; Richard J B Dobson; Aroon Hingorani; Riyaz Patel; Jonathan Sterne; Amitava Banerjee; Alastair K Denniston; Simon Ball; Neil J Sebire; Nigam H Shah; Graham R Foster; Bryan Williams; Harry Hemingway Journal: BMC Med Inform Decis Mak Date: 2021-10-12 Impact factor: 2.796